Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing

Chuikyo General Assembly Meeting on Feb. 15 An all-powerful Japanese reimbursement policy panel on February 15 approved the basic pricing and post-listing price adjustment plan for Shionogi’s COVID-19 pill Xocova (ensitrelvir). The re-pricing threshold based on estimated sales data was...read more